<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7412427\results\search\testTrace\results.xml">
  <result pre="Emerging viral resistance to the neuraminidase inhibitor oseltamivir limits the" exact="treatment" post="of acute influenza infections. Targeting influenza virus-host interactions is"/>
  <result pre="the combination of virus- and host-directed drugs might significantly improve" exact="treatment" post="success. We therefore assessed the combined treatment with oseltamivir"/>
  <result pre="might significantly improve treatment success. We therefore assessed the combined" exact="treatment" post="with oseltamivir and the repurposed antifungal drug itraconazole on"/>
  <result pre="treatment with oseltamivir and the repurposed antifungal drug itraconazole on" exact="infection" post="of polarized broncho-epithelial Calu-3 cells with pdm09 or Panama"/>
  <result pre="strains. We detected significantly stronger antiviral activities in the combined" exact="treatment" post="compared to monotherapy with oseltamivir, permitting lower concentrations of"/>
  <result pre="shift) [5]. Thus, antiviral drugs are essential additions for effective" exact="infection" post="control. To initiate the infection process, the hemagglutinin (HA)"/>
  <result pre="are essential additions for effective infection control. To initiate the" exact="infection" post="process, the hemagglutinin (HA) protruding from the envelope of"/>
  <result pre="the vital functions of sialic acid residues in the IAV" exact="infection" post="process, the viral NA constitutes an attractive target for"/>
  <result pre="NA inhibitors such as oseltamivir are still recommended for influenza" exact="treatment" post="[13,14,15]. However, the emergence of oseltamivir-resistant IAV and IBV"/>
  <result pre="in the last decade [12]. A novel endonuclease inhibitor for" exact="treatment" post="of influenza A and influenza B infection, baloxavir marboxil"/>
  <result pre="of antiviral medication, especially because of the approval extension for" exact="treatment" post="of high-risk patients, oseltamivir is still the leading, most"/>
  <result pre="is still the leading, most commonly used drug in influenza" exact="infection" post="treatment. The second class of approved antivirals are the"/>
  <result pre="subtypes, the adamantanes are not recommended anymore for prophylaxis and" exact="treatment" post="[17,18]. The ability of IAV to rapidly develop resistance"/>
  <result pre="successful replication process is an emerging approach to counteract viral" exact="infection" post="[19,20,21,22,23]. Because the pathogens critically depend on the host"/>
  <result pre="from host-directed therapy (HDT) would require substantial changes in the" exact="infection" post="cycle and is, therefore, much less likely to occur"/>
  <result pre="crucial role of host cell cholesterol homeostasis in the IAV" exact="infection" post="cycle. Indeed, we could identify the late endosomal cholesterol"/>
  <result pre="in vitro and in a preclinical murine model of IAV" exact="infection" post="[24]. Combination therapy, i.e., the treatment of influenza virus"/>
  <result pre="murine model of IAV infection [24]. Combination therapy, i.e., the" exact="treatment" post="of influenza virus infection with at least two drugs"/>
  <result pre="infection [24]. Combination therapy, i.e., the treatment of influenza virus" exact="infection" post="with at least two drugs with different modes of"/>
  <result pre="drug oseltamivir and the host-directed anti-infective drug itraconazole on IAV" exact="infection" post="in a cell culture model of polarized bronchial cell"/>
  <result pre="washed with PBS and were inoculated at a multiplicity of" exact="infection" post="(MOI) of 0.1 of virus diluted in infection-PBS (PBS"/>
  <result pre="of itraconazole at a given concentration, Eobserved, effect of combined" exact="treatment" post="at given concentrations. Î&quot;E &amp;gt; 0 indicates antagonism, Î&quot;E"/>
  <result pre="share this fate. To analyze the effect of a combination" exact="treatment" post="with oseltamivir and the host-targeting drug itraconazole, we selected"/>
  <result pre="submerged in media on semipermeable supports as an in vitro" exact="infection" post="model. After four days of cultivation, the adherent monolayer"/>
  <result pre="polarization of the confluent epithelial monolayers. We first tested whether" exact="treatment" post="with any of the drugsâ€&quot;single or combinedâ€&quot;affected cell survival."/>
  <result pre="Figure 9, resulted in consistent patterns across the models. For" exact="infection" post="with pdm09, 0.25 ÂµM itraconazole tended to antagonize oseltamivir"/>
  <result pre="effects. 4. Discussion We analyzed the antiviral effects of combined" exact="treatment" post="with the IAV neuraminidase-targeting drug oseltamivir and itraconazole, a"/>
  <result pre="LE compartment is a critical host/pathogen interface in the IAV" exact="infection" post="cycle, since the fusion of the IAV envelope with"/>
  <result pre="found that increased cholesterol accumulation via NPC1 blockade impacts IAV" exact="infection" post="at multiple steps, (i) by impairing the virus/endosome fusion,"/>
  <result pre="a drug-repurposing approach in a preclinical mouse model of IAV" exact="infection" post="[24]. The EC50 values for itraconazole-mediated antiviral activity against"/>
  <result pre="underscoring that itraconazole is indeed a promising candidate for the" exact="treatment" post="of IAV infections [24]. Such drugs that target host"/>
  <result pre="influenza virus NA inhibitor oseltamivir, is less likely [20,21]. Indeed," exact="screening" post="libraries of already approved compounds for novel uses (drug"/>
  <result pre="from the inappropriate time window of application (early vs. late" exact="infection" post="stages) and a suppression rather than a complete elimination"/>
  <result pre="than a complete elimination of the infectious agent, requiring long" exact="treatment" post="duration which is often associated with poor patient compliance."/>
  <result pre="itraconazole might function as a safeguard mechanism to combat IAV" exact="infection" post="caused by strains with heightened oseltamivir resistance. Clinical translation"/>
  <result pre="Results from our previous study exploring the benefit of itraconazole" exact="treatment" post="in IAV-infected mice already documented the antiviral activity in"/>
  <result pre="obtained in this study may help design trials in the" exact="treatment" post="of influenza virus infections. Acknowledgments We thank Jonathan Hentrey"/>
  <result pre="anti-influenza activity: Present and future of strategies for the optimal" exact="treatment" post="and management of influenza. Part I: Influenza life-cycle and"/>
  <result pre="Physiol.2017441083108810.1111/1440-1681.1282228744925 37.LestnerJ.HopeW.W.Itraconazole: An update on pharmacology and clinical use for" exact="treatment" post="of invasive and allergic fungal infectionsExpert Opin. Drug Metab."/>
  <result pre="values. Figure 6 Analysis of the anti-IAV activity of combination" exact="treatment" post="with oseltamivir and itraconazole. Polarized Calu-3 monolayers were infected"/>
  <result pre="viral titers Â± SEM were compared to the respective oseltamivir" exact="treatment" post="without itraconazole. Data are expressed as differences and 95%"/>
  <result pre="cells indicate inhibition â‰¥90% for combinations, with the individual drug" exact="treatment" post="reaching inhibition â‰¤90%. Red cells indicate combinations leading to"/>
  <result pre="oseltamivir concentration. Figure 9 Assessment of synergistic effects of combined" exact="treatment" post="with oseltamivir and itraconazole. Bliss independence, Loewe additivity and"/>
 </snippets>
</snippetsTree>
